These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 17298352)

  • 21. Are Allergen Immunotherapy Dose Adjustments Needed for Local Reactions, Peaks of Season, or Gaps in Treatment?
    Epstein TE; Tankersley MS
    J Allergy Clin Immunol Pract; 2017; 5(5):1227-1233. PubMed ID: 28709818
    [No Abstract]   [Full Text] [Related]  

  • 22. [The mechanisms of allergen-specific immunotherapy more clear].
    Rak S
    Lakartidningen; 2008 Jun 25-Jul 1; 105(26-27):1935-7. PubMed ID: 18681375
    [No Abstract]   [Full Text] [Related]  

  • 23. Regulatory control and standardization of allergenic extracts.
    Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M; 1988; (82):177-220. PubMed ID: 3196018
    [No Abstract]   [Full Text] [Related]  

  • 24. Evaluation of allergen vaccine potency.
    Esch RE
    Curr Allergy Asthma Rep; 2006 Sep; 6(5):402-6. PubMed ID: 16899202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Instructions and consent forms for subcutaneous allergen immunotherapy.
    Cox L; Lockey RF
    Clin Allergy Immunol; 2008; 21():499-525. PubMed ID: 18828526
    [No Abstract]   [Full Text] [Related]  

  • 26. Medication with antihistamines impairs allergen-specific immunotherapy in mice.
    Johansen P; Senti G; Maria Martínez Gómez J; Kündig TM
    Clin Exp Allergy; 2008 Mar; 38(3):512-9. PubMed ID: 18081882
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adverse effects and fatalities associated with subcutaneous allergen immunotherapy.
    Bukantz SC; Bagg AS; Lockey RF
    Clin Allergy Immunol; 2008; 21():455-68. PubMed ID: 18828523
    [No Abstract]   [Full Text] [Related]  

  • 28. Skin prick testing in biological standardization of allergenic products.
    Malling HJ
    Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M; 1997; (91):157-63. PubMed ID: 9383905
    [No Abstract]   [Full Text] [Related]  

  • 29. [Governmental batch sample testing of allergen products].
    Bartel D; Führer F; Vieths S
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2012 Mar; 55(3):358-62. PubMed ID: 22373849
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treating allergy: where to from here?
    O'Hehir RE
    Intern Med J; 2009 Aug; 39(8):491-4. PubMed ID: 19732196
    [No Abstract]   [Full Text] [Related]  

  • 31. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial.
    Senti G; Johansen P; Haug S; Bull C; Gottschaller C; Müller P; Pfister T; Maurer P; Bachmann MF; Graf N; Kündig TM
    Clin Exp Allergy; 2009 Apr; 39(4):562-70. PubMed ID: 19226280
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Desensitization with allergens: early, specific, effective therapy of immune system almost without side effects. Interview by Dr. Barbara Scholtissek].
    Fiebig H; Kahlert H
    Wien Med Wochenschr; 1999; 149(14-15):447, 449-50. PubMed ID: 10584292
    [No Abstract]   [Full Text] [Related]  

  • 33. Food and Drug Administration reclassification of allergens for diagnosis and treatment: now is the time to be heard.
    Larenas-Linnemann DE; Finegold I; Nelson H
    Ann Allergy Asthma Immunol; 2012 Jul; 109(1):6-9. PubMed ID: 22727150
    [No Abstract]   [Full Text] [Related]  

  • 34. [Adverse effects monitoring in allergen specific immunotherapy].
    Mosbech HF
    Ugeskr Laeger; 2006 Mar; 168(11):1105. PubMed ID: 16545211
    [No Abstract]   [Full Text] [Related]  

  • 35. Allergen-related approaches to immunotherapy.
    Rolland JM; Gardner LM; O'Hehir RE
    Pharmacol Ther; 2009 Mar; 121(3):273-84. PubMed ID: 19111571
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quality and clinical efficacy of allergen mixtures.
    Malling HJ
    Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M; 2006; (95):253-7; discussion 257. PubMed ID: 17393747
    [No Abstract]   [Full Text] [Related]  

  • 37. EAACI guidelines on allergen immunotherapy: Executive statement.
    Muraro A; Roberts G; Halken S; Agache I; Angier E; Fernandez-Rivas M; Gerth van Wijk R; Jutel M; Lau S; Pajno G; Pfaar O; Ryan D; Sturm GJ; van Ree R; Varga EM; Bachert C; Calderon M; Canonica GW; Durham SR; Malling HJ; Wahn U; Sheikh A
    Allergy; 2018 Apr; 73(4):739-743. PubMed ID: 29380390
    [No Abstract]   [Full Text] [Related]  

  • 38. Are we following practice parameter guidelines on allergen immunotherapy?
    Chacko T
    Ann Allergy Asthma Immunol; 2008 Feb; 100(2):178. PubMed ID: 18320926
    [No Abstract]   [Full Text] [Related]  

  • 39. EAACI guidelines on allergen immunotherapy-Out with the old and in with the new.
    Agache I
    Allergy; 2018 Apr; 73(4):737-738. PubMed ID: 29319886
    [No Abstract]   [Full Text] [Related]  

  • 40. Allergen stability of testing/treatment boards and immunotherapy vials with various diluents.
    Nida A; Leatherman B; Plunkett G; Mire B
    Int Forum Allergy Rhinol; 2015 Nov; 5(11):1028-35. PubMed ID: 26153653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.